Non-Hodgkin lymphoma market to grow to $9.2 billion

29 October 2014

The non-Hodgkin lymphoma (NHL) market will be worth $9.2 billion by 2020, according to new research.

This is up from $5.6 billion in 2013 at a modest compound annual growth rate (CAGR) of 7.4%. This growth will be driven by the expected launch of promising drugs, including novel small molecule inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Roche’s Rituxan/Mabthera (rituximab).

The launch of a premium-priced novel glycol-engineered antibody; obinutuzumab; the personalized vaccine dasiprotimut-T, mTOR inhibitor everolimus, and several kinase inhibitors including Gilead Sciences’ Zydelig (idelalisib) and Imbruvica (ibrutinib) from Pharmacyclics/Janssen Biotech (which gained US Food and Drug Administration approval in July) are expected to have a significant impact on the market size.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK